The Effect of Comorbidities on Asthma-Related Outcomes Over a Two-Year Period: A Prospective Analysis of Swiss Severe Asthma Registry (SSAR)

合并症对哮喘相关结局两年内的影响:瑞士重症哮喘登记处(SSAR)的前瞻性分析

阅读:1

Abstract

PURPOSE: Severe asthma is frequently accompanied by comorbidities such as chronic rhinosinusitis, nasal polyps, allergies, and gastroesophageal reflux disease (GERD). With increasing age, non-communicable conditions such as cardiovascular diseases and multimorbidity become more prevalent. This study aimed to analyze the prevalence of comorbidities and their impact on asthma-related outcomes over a two-year period using data from the Swiss Severe Asthma Registry (SSAR). PATIENTS AND METHODS: We included 234 patients with baseline data and 2 years of follow-up visits from the SSAR. Patient's asthma control (ACT), quality of life (QoL), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), diffusing capacity of the lungs for carbon monoxide (DLCO) and fraction expiratory nitric oxide (FeNO) and their association to comorbidities were analyzed longitudinally using general estimation equations (GEEs) with log link function. RESULTS: Over the study period, ACT and QoL scores significantly improved, and the frequency of exacerbations declined. The prevalence of the examined comorbidities remained stable. However, the presence of chronic obstructive pulmonary disease (COPD) was significantly associated with lower ACT scores, reduced QoL, and impaired pulmonary function (all p < 0.05). GERD was also linked to lower ACT and QoL (p < 0.05), while depression was associated with a significant decrease in DLCO (p < 0.05). CONCLUSION: Our findings underscore the strong impact of comorbidities-particularly COPD, GERD, and depression-on asthma control, quality of life, and lung function in patients with severe asthma. These results highlight the need for integrated, multidisciplinary management strategies targeting comorbid conditions to improve overall asthma outcomes. Further research should explore these subgroups in more detail to guide personalized treatment approaches.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。